Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London

Tiziana Life Sciences (TLSA) will present at the Jefferies Healthcare Conference in London on November 18, 2026. The company will discuss its Phase 2a INFORM-MS trial results for intranasal foralumab in non-active secondary progressive multiple sclerosis, which met primary endpoints and showed clinical improvements. Management will also be available for one-on-one meetings.

Original reporting
Published Nov 12, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 2:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TLSA
Bullish
high confidence
Mentioned
$TLSA
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$TLSABullishMed
01

Why it matters

The Phase 2a results provide the first efficacy readout for foralumab in secondary progressive MS, a key milestone for the company's pipeline.

02

Market read

Positive trial data may trigger short‑term buying interest and set the stage for future funding rounds.

03

What to watch

Potential regulatory delays and competition from other anti‑CD3 programs could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Tiziana Life Sciences (TLSA) is a clinical‑stage biotech focused on intranasal delivery of immunomodulatory antibodies.

Company-level read

Ticker impact

$TLSABullishHigh confidence
Context

TLSA announced positive Phase 2a INFORM-MS trial results and will present at the Jefferies Healthcare Conference.

Expected impact

likely upward pressure as investors price in the favorable trial outcomes

Evidence & confidence

The trial met primary endpoints with statistical significance and safety signals, a material catalyst for a clinical‑stage biotech.

Market effects

Strengthens the neuro‑inflammation biotech niche and may lift peer companies developing intranasal immunotherapies.

Limited to U.S. biotech investors; no broader regional effect.

Modest; primarily relevant to specialty biotech investors.

Counterpoint

If the data cannot be replicated in larger trials, the initial hype may fade.

Key entities

  • Tiziana Life Sciences Ltd.

    Biotech developing intranasal foralumab.

  • Jefferies Healthcare Conference

    Venue where TLSA will present its data.

Related articles

$TLSAHighAI 8/10

Tiziana Life Sciences Ltd.: Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Scler

Tiziana Life Sciences (TLSA) reported positive Phase 2a INFORM-MS trial results for its lead drug, intranasal foralumab, in treating non-active secondary progressive multiple sclerosis (na-SPMS). Key findings include statistically significant reductions in microglial activation and improvements in fatigue. The results align with longer-term data from the company's expanded access program, showing EDSS stabilization and improvement.

$TLSAHighAI 9/10

A nasal drug for MS reduced a brain inflammation measure in a 12-week trial

Tiziana Life Sciences (TLSA) reported positive Phase 2a trial results for its intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS). The trial met primary endpoints, showing a statistically significant reduction in microglial activation and clinically meaningful fatigue improvements. The company will host a conference call to discuss the results, with key opinion leaders presenting the data. TLSA plans to engage with the FDA for next steps in development.

$TLSAHighAI 8/10

Tiziana's Intranasal Foralumab Meets Primary Endpoints In Phase 2a Multiple Sclerosis Trial

Tiziana Life Sciences (TLSA) reported that its Phase 2a trial of intranasal foralumab met primary endpoints, reducing neuroinflammation and demonstrating safety in non-active secondary progressive multiple sclerosis (na-SPMS) patients. The study showed significant reductions in microglial activation and improvements in fatigue symptoms. TLSA plans to discuss results with the FDA. The stock closed at $0.67 on Monday, up 14.87% in overnight trading.